Do you work in the press or media?

The information on this page is intended for journalists, press and media. Click YES to get to the newsroom. If you click NO you will come back to Mynewsdesk.com.

Skip to content

News archive
Media library (current)
Contact

News archive
Media library (current)
Contact

Search in newsroom

Media library

Type

Category

Search in media library

Klas Kärre, Anocca scientific advisory board member

License:

Media Use

File format:

.jpg

Size:

512 x 774, 198 KB

more info...
Download
Rolf Kiessling, Anocca scientific advisory board member

License:

Media Use

File format:

.jpg

Size:

512 x 774, 184 KB

more info...
Download
Exterior of Anocca's GMP facility

License:

Media Use

File format:

.jpg

Size:

1800 x 900, 354 KB

more info...
Download
Anocca's BioStart Programme

License:

Media Use

File format:

.jpg

Size:

3024 x 4032, 1.34 MB

more info...
Download
Anocca's BioStart Programme

License:

Media Use

File format:

.jpg

Size:

3024 x 4032, 1.88 MB

more info...
Download
Anocca's BioStart Programme

License:

Media Use

File format:

.jpg

Size:

3024 x 4032, 1.5 MB

more info...
Download
Martin Welschof, Anocca board member

License:

All rights reserved

File format:

.jpg

Size:

640 x 823, 75.2 KB

more info...
Christiane Hanke-Harloff, Anocca board member

License:

All rights reserved

File format:

.jpg

Size:

640 x 480, 66.8 KB

more info...
Sophie Blomqvist, Anocca board member

License:

Media Use

File format:

.jpg

Size:

1854 x 2317, 2.71 MB

more info...
Download
Hans Stråberg, Anocca chairman of the board

License:

Media Use

File format:

.jpg

Size:

1854 x 2317, 2.84 MB

more info...
Download
Jan Lundberg, Anocca board member

License:

Media Use

File format:

.jpg

Size:

1625 x 2031, 2.3 MB

more info...
Download
Mikael Blomqvist, Anocca co-founder and board member

License:

Media Use

File format:

.jpg

Size:

2043 x 2554, 3.83 MB

more info...
Download

Show more Loading...

Built by nature, engineered by Anocca

Anocca is a fully integrated biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. Its unique discovery engine uses programmable human cells to recreate and manipulate T cell immunity. This proprietary technology scales TCR-T cell therapy development, allowing the systematic generation of personalised treatments for the broadest patient populations.

Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and in-house cGMP manufacturing and process development facilities. All Anocca’s therapeutic TCRs are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca’s facilities in Sweden.

Anocca AB

Forskargatan 20C
151 36 Södertälje
Sweden

Go to mynewsdesk.com

Try Mynewsdesk
For journalists
Find more stories
Log in

Enter your email address to follow Anocca AB

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.

Accept Terms of Use, Privacy Policy and Privacy Policy for Contacts

Check your inbox

Email sent to __email__. Click the link there to follow Anocca AB.

Okay